Calcium ： High Blood Pressure (Hypertension)
C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。Small meta-analytic BP reduction (-1.4 mmHg systolic). Overwhelmed by cardiovascular safety concerns from supplement studies. Dietary calcium preferred.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'heartcited.com';
const params = 'ingredient\u003Dcalcium\u0026condition\u003Dhigh\u002Dblood\u002Dpressure';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
結論
Small meta-analytic BP reduction (-1.4 mmHg systolic). Overwhelmed by cardiovascular safety concerns from supplement studies. Dietary calcium preferred.
Key Study Findings
Meta-Analysis
Associations between Diet and Cognitive Function in Stroke Survivors: A Systematic Review and Meta-analysis.
Dose: None
vs: Standard care or placebo
Outcome: Global cognition in stroke survivors
効果: SMD=0.62 (energy-protein); SMD=-0.40 (B-vitamins)
0.009 (protein); 0.02 (B-vit)
対象集団: Adult stroke survivors (20 trials + 14 observational)
Review
Dietary supplements and prevention of preeclampsia.
Dose: 500 mg daily
vs: Placebo
Outcome: Preeclampsia risk reduction
効果: ~50% risk reduction
None
対象集団: Pregnant women with low calcium intake
Review
Novel pharmacologic approaches in resistant hypertension.
Dose: Spironolactone, sacubitril/valsartan, SGLT2i
vs: None
Outcome: Blood pressure control in resistant HTN
効果: None
None
対象集団: Patients with resistant hypertension
Review
Vegan Diet Health Benefits in Metabolic Syndrome.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Adults with metabolic syndrome
cross-sectional observational study
n=260
Restless leg syndrome in chronic hemodialysis patients in Mashhad hemodialysis centers.
Dose: None
vs: Placebo
効果: None
None
Observational Study
n=40
Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
Dose: anti-digoxin antibodies (Fab)
vs: pre-treatment
Outcome: serum digoxin and clinical outcomes
効果: Fab bound digoxin; no improved clinical outcomes
None
対象集団: Chronic digoxin toxicity patients
Key Statistics
13
研究数
1500
参加者数
↔
Mixed
C
グレード
Referenced Papers
Hypertension research : …
2025
10 件の引用
Associations between Diet and Cognitive Function in Stroke Survivors: A Systematic Review and Meta-analysis.
Meta-Analysis
Advances in nutrition …
2025
1 件の引用
Wiadomosci lekarskie (Warsaw, …
2024
Nutrients
2021
113 件の引用
Journal of renal …
2017
26 件の引用
Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).
Observational
Clinical toxicology (Philadelphia, …
2016
25 件の引用
Trends in cardiovascular …
2016
19 件の引用
Nephro-urology monthly
2014
43 件の引用
Zhongguo Zhong yao …
2014
4 件の引用
British journal of …
2013
156 件の引用
Acta medica Indonesiana
2007
4 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- note:
- Prefer dietary sources; limit supplements to 500 mg/dose
- general:
- 1,000-1,200 mg/day from diet plus supplements
上限量： 2,000-2,500 mg/day (total from diet and supplements)
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| 500 mg daily | -- | Positive | -- |
| Spironolactone, sacubitril/valsartan, SGLT2i | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Neutral | 260 |
| anti-digoxin antibodies (Fab) | -- | Neutral | 40 |
| None | -- | Mixed | -- |
| None | -- | Neutral | 2991 |
推奨摂取タイミング： Divide doses (500 mg max per dose); carbonate with meals; citrate any time
Safety & Side Effects
報告されている副作用
- ⚠ Constipation (especially carbonate form)
- ⚠ Potential increased MI risk with high-dose supplements (controversial)
- ⚠ Kidney stones at excessive doses
- ⚠ Gas, bloating
既知の相互作用
- ● Thyroid medications (separate by 4 hours)
- ● Bisphosphonates (separate by 30-60 minutes)
- ● Iron supplements (reduced absorption — separate by 2 hours)
- ● Certain antibiotics (reduced absorption)
- ● Vitamin K2 (may help direct supplemental calcium to bones, not arteries)
耐容上限摂取量： 2,000-2,500 mg/day (total from diet and supplements)
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Calcium help with High Blood Pressure (Hypertension)?
Based on 13 studies with 1,500 participants, there is limited but promising evidence that Calcium may support High Blood Pressure (Hypertension) management. Our evidence grade is C (Some Evidence).
How much Calcium should I take for High Blood Pressure (Hypertension)?
Studies have used various dosages. A commonly studied range is Prefer dietary sources; limit supplements to 500 mg/dose. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Calcium?
Reported side effects may include Constipation (especially carbonate form), Potential increased MI risk with high-dose supplements (controversial), Kidney stones at excessive doses, Gas, bloating. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Calcium and High Blood Pressure (Hypertension)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 13 peer-reviewed studies with 1,500 total participants. The overall direction of effect is mixed.
Related Evidence
に関する他の成分： High Blood Pressure (Hypertension)
References
- [1] Takafumi Ushida et al.. Hypertens Res. 2025. Dietary supplements and prevention of preeclampsia. doi:10.1038/s41440-025-02144-9 PubMed
- [2] Sasan Amanat et al.. Adv Nutr. 2025. Associations between Diet and Cognitive Function in Stroke Survivors: A Systematic Review and Meta-analysis. doi:10.1016/j.advnut.2025.100440 PubMed
- [3] Jerzy Głuszek. Wiad Lek. 2024. Novel pharmacologic approaches in resistant hypertension. doi:10.36740/WLek/194090 PubMed
- [4] Giulia Marrone et al.. Nutrients. 2021. Vegan Diet Health Benefits in Metabolic Syndrome. doi:10.3390/nu13030817 PubMed
- [5] Niloufar Zadeh Saraji et al.. J Renal Inj Prev. 2017. Restless leg syndrome in chronic hemodialysis patients in Mashhad hemodialysis centers. doi:10.15171/jrip.2017.27 PubMed
- [6] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
- [7] Alfonso Eirin et al.. Trends Cardiovasc Med. 2016. Emerging concepts for patients with treatment-resistant hypertension. doi:10.1016/j.tcm.2016.05.004 PubMed
- [8] Behzad Einollahi et al.. Nephrourol Mon. 2014. Restless leg syndrome: a neglected diagnosis. doi:10.5812/numonthly.22009 PubMed
- [9] Jian-hong Li et al.. Zhongguo Zhong Yao Za Zhi. 2014. [Clinical characteristics and combined use of medicine analysis of 2 991 hospitalized patients with psoriasis based on real world database]. PubMed
- [10] S Basit. Br J Biomed Sci. 2013. Vitamin D in health and disease: a literature review. doi:10.1080/09674845.2013.11669951 PubMed
- [11] Eka Ginanjar et al.. Acta Med Indones. 2007. Vitamin D and autoimmune disease. PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。